14.27
Acadia Pharmaceuticals Inc stock is traded at $14.27, with a volume of 1.04M.
It is down -0.70% in the last 24 hours and down -14.95% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$14.38
Open:
$14.6
24h Volume:
1.04M
Relative Volume:
0.65
Market Cap:
$2.50B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
79.25
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
-4.74%
1M Performance:
-14.95%
6M Performance:
-1.65%
1Y Performance:
-15.95%
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ACAD
Acadia Pharmaceuticals Inc
|
14.27 | 2.50B | 890.53M | 30.57M | 80.53M | 0.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.15 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.23 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.94 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.89 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.05 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-11-25 | Initiated | Deutsche Bank | Hold |
Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
Mar-12-24 | Reiterated | Needham | Buy |
Jan-30-24 | Initiated | Robert W. Baird | Outperform |
Jan-24-24 | Upgrade | Needham | Hold → Buy |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-13-23 | Initiated | Citigroup | Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
Oct-17-23 | Initiated | UBS | Buy |
Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
Nov-01-22 | Initiated | Loop Capital | Hold |
Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-21 | Resumed | Needham | Hold |
Jun-10-21 | Initiated | Berenberg | Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-21 | Downgrade | Stifel | Buy → Hold |
Dec-16-20 | Initiated | Mizuho | Buy |
Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-20-20 | Initiated | Morgan Stanley | Overweight |
Jul-07-20 | Upgrade | Stifel | Hold → Buy |
Apr-16-20 | Initiated | Jefferies | Buy |
Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
Mar-06-20 | Initiated | Citigroup | Buy |
Dec-16-19 | Initiated | Guggenheim | Buy |
Oct-24-19 | Initiated | Oppenheimer | Perform |
Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
Jul-23-19 | Reiterated | Needham | Buy |
Dec-10-18 | Initiated | Canaccord Genuity | Hold |
Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-09-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Initiated | Stifel | Hold |
Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus
BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com
Schizophrenia Market to Reach New Heights in Growth by 2034, - openPR.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance
Lobbying Update: $20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Li - GuruFocus
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Neuroscience Leader Acadia Expands Team with Major Equity Compensation Package - Stock Titan
Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock - Investing.com Australia
Acadia Pharmaceuticals CFO sells $40,132 in stock - Investing.com India
Acadia Pharmaceuticals CFO sells $40,132 in stock By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals Executives Sell Shares to Cover Taxes - TradingView
Is Weakness In ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance
Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India
Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR
Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey
ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily
Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN
Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire
Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia
Acadia Pharmaceuticals issues new employee stock awards - Investing.com India
Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
Parkinson's Disease Therapeutics Market is expected to reach - openPR
ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com
Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360
SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):